Labcorp Unveils Plasma Detect MRD Technology Advancing Cancer Detection and Treatment

Labcorp Holdings Inc. has announced that its Labcorp Plasma Detect™, a tumor-informed, blood-based assay for detecting molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two peer-reviewed publications: Nature Medicine and Clinical Cancer Research. The studies have already been published and demonstrate the clinical utility of Labcorp Plasma Detect in cancer research. In Nature Medicine, researchers reported that the assay successfully tracked early disease progression and predicted long-term progression-free survival in patients with diffuse pleural mesothelioma undergoing immune-based treatment regimens before surgery. In Clinical Cancer Research, the assay was used to compare lymph fluid and plasma samples after head and neck cancer surgery, showing that lymph-based testing identified residual cancer more effectively than traditional methods. These findings suggest that Labcorp Plasma Detect may inform treatment strategies and improve post-surgical monitoring in cancer care. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC28591) on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)